Payment overview · 2025
General Payments
$1,106.35
43 reported records · 8 companies
Healthcare provider profile · identity verified
Heather Lecomte Joslin, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · FAYETTEVILLE, NC · NPI 1669941928
Verified facts
What the public records show
CMS Open Payments records show Heather Lecomte Joslin, FNP received $1,106.35 in general payments during 2025 across 43 reported records.
AstraZeneca Pharmaceuticals LP accounted for 49.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Airsupra, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $547.59 | 49.5% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $220.83 | 20.0% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $170.98 | 15.4% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $57.72 | 5.2% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.20 | 3.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.01 | 3.0% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.61 | 1.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.41 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,106.35 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $498.28 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $245.19 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $90.08 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $80.90 | 5 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $66.77 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $57.72 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $57.72 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $40.39 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $35.20 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $35.20 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $30.92 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.92 | 3 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $20.61 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AIRSUPRA airsupra |
2025 | Airsupra | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 68 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
36 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
68 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
82 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
67 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 285 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 251 | 68 |
| Omeprazole | Omeprazole | 238 | 65 |
| Lisinopril | Lisinopril | 212 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 195 | 74 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 194 | 66 |
| Gabapentin | Gabapentin | 187 | 55 |
| Metformin Hcl | Metformin Hcl | 145 | 37 |
| Montelukast Sodium | Montelukast Sodium | 134 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 131 | 36 |
| Losartan Potassium | Losartan Potassium | 126 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 120 | 39 |
| Prednisone | Prednisone | 118 | 89 |
| Alprazolam | Alprazolam | 115 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 42 |
| Celecoxib | Celecoxib | 103 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 102 | 25 |
| Furosemide | Furosemide | 100 | 34 |
| Buspirone Hcl | Buspirone Hcl | 97 | 32 |
| Sertraline Hcl | Sertraline Hcl | 95 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 95 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 26 |
| Azithromycin | Azithromycin | 89 | 77 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 20 |
| Ozempic | Semaglutide | 82 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 81 | 30 |
| Trazodone Hcl | Trazodone Hcl | 80 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 23 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 75 | 20 |
| Ezetimibe | Ezetimibe | 69 | 24 |
| Ibuprofen | Ibuprofen | 69 | 19 |
| Mounjaro | Tirzepatide | 68 | 20 |
| Eliquis | Apixaban | 67 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 67 | 20 |
| Carvedilol | Carvedilol | 65 | 16 |
| Famotidine | Famotidine | 61 | 13 |
| Meloxicam | Meloxicam | 59 | 27 |
| Glipizide Er | Glipizide | 57 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 15 |
| Simvastatin | Simvastatin | 57 | 20 |
| Potassium Chloride | Potassium Chloride | 55 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 14 |
| Nystatin | Nystatin | 54 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 53 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 51 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 15 |
| Bupropion Xl | Bupropion Hcl | 49 | 14 |
| Fluconazole | Fluconazole | 49 | 34 |
| Clonazepam | Clonazepam | 48 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 14 |
| Mupirocin | Mupirocin | 46 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 12 |
| Pregabalin | Pregabalin | 43 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 40 | 15 |
| Promethazine Hcl | Promethazine Hcl | 40 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 39 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 37 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Linzess | Linaclotide | 36 | 13 |
| Amoxicillin | Amoxicillin | 35 | 31 |
| Ondansetron Odt | Ondansetron | 35 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Cephalexin | Cephalexin | 32 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 24 |
| Allopurinol | Allopurinol | 24 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | 14 |
| Valacyclovir | Valacyclovir Hcl | 22 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,106.35 · 43 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BOTOX, BREZTRI, Cologuard Collection Kit, MOUNJARO, NURTEC ODT, Ozempic, PURIFIED CORTROPHIN GEL, QULIPTA, Rybelsus, Symbravo, The Cologuard Plus Collection Kit, UBRELVY, Wegovy, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Airsupra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error